Browse Studies — Arctuva

Phase 3

A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based…

NSCLCNon-small Cell Lung CancerNon-Small Cell Lung Cancer NSCLC+4 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT07777822

Phase 2

Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) a…

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor

Estimated

~$10 – $8,750

CatalYm GmbHNCT07246863

Phase 2

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) v…

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor

Estimated

~$10 – $8,750

CatalYm GmbHNCT07098988